Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Advanced Therapeutics
ISSN 2366-3987 · Wiley-Blackwell
Advanced Therapeutics: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.06; hybrid open access; APC about USD 4,430; median 132 days to acceptance (24 articles, last 24 months); acceptance rate 23% (journal website); 167 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Advanced Therapeutics is published by Wiley-Blackwell and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Nanoplatforms for cancer theranostics, Nanoparticle-Based Drug Delivery and RNA Interference and Gene Delivery, together about 38.3% of its articles. Its main subfields are Biomedical Engineering and Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
The Advanced Portfolio from Wiley is a family of globally respected, high-impact journals publishing cutting-edge science.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Editor-in-chief Christine MayerPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nanoplatforms for cancer theranosticsEngineering17.6%
- Nanoparticle-Based Drug DeliveryMaterials Science10.7%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology9.9%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.9%
- Advanced biosensing and bioanalysis techniquesBiochemistry, Genetics and Molecular Biology4.2%
- 3D Printing in Biomedical ResearchEngineering3.9%
- Extracellular vesicles in diseaseBiochemistry, Genetics and Molecular Biology3.9%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.06LetPub ·
- Impact factor (publisher)
- 3.2Publisher website ·
- Impact factor (publisher) 2025
- 3.2Publisher website ·
- CiteScore 2026-06
- 4.9LetPub ·
- CiteScore (publisher)
- 4.9Publisher website ·
- CiteScore (publisher) 2025
- 4.9Publisher website ·
- SJR 2026-06
- 0.65LetPub ·
- SNIP 2026-06
- 0.47LetPub ·
- h-index
- 58OpenAlex ·
- i10-index
- 531OpenAlex ·
- 2-year mean citedness
- 3.09OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 34.22%LetPub ·
Volume
- Articles per year
- 130LetPub ·
- Articles per year (publisher) 2025
- 131Publisher website ·
- Downloads per year (publisher) 2025
- 285,788Publisher website ·
Articles by year OpenAlex count · 1,457 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 79 | 30 | 38 |
| 2025 | 167 | 95 | 412 |
| 2024 | 204 | 119 | 942 |
| 2023 | 212 | 138 | 1,517 |
| 2022 | 160 | 60 | 1,336 |
| 2021 | 169 | 88 | 2,726 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
132 daysMedian, submission to acceptance · P25–P75 100 days – 182 days
- Acceptance to online
- median 11 days (25 articles)
- Submission to online
- median 140 days
- Sample
- 24 articles with submission and acceptance dates (271 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Acceptance rate (publisher)
- 23%Publisher website ·
- Acceptance rate (publisher) 2025
- 23%Publisher website ·
- Submission to first decision
- 10 daysPublisher website ·
- Submission to first decision 2025
- 10 daysPublisher website ·
- Submission to acceptance 2025
- 126 daysPublisher website ·
- Acceptance to publication 2025
- 15 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,430 / EUR 3,700 / GBP 3,010 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 200 words
- Keywords
- ≥ 3
- Reference style
- Numbered, in order of citation
- Templates
- LaTeX and Word
- First submission
- Free format: the journal's layout is not required
Article types accepted3, with length limits
- perspectivePerspectives are peer-reviewed and provide a forum to present personal opinions and backgrounds on topics of interest to national and international research com…main text ≤ 200 words · abstract ≤ 200 words
- research articleX manuscript template. Whilst a typical Research Article is around 3000–8000 words (in its entirety) including 3–8 display items (figures, schmain text ≤ 8,000 words
- reviewReviews are peer-reviewed and give an overview of recent progress in important fields of research, providing the readers with a guide to the relevant literature…abstract ≤ 200 words · figures and tables ≤ 15
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, Open access, Peer review
- AI use AI-Generated Images
For information about using AI-generated images in your work, please see Wiley’s AI Guidelines for Researchers.
Source ↗Publisher website ·- Authorship Authorship
The list of authors should accurately indicate who contributed to the work. All those listed as authors should qualify for authorship according to the following criteria: Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; Been involved in drafting the manuscript or revising it critically for important intellectual content; …
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest
All authors must declare financial/commercial conflicts of interest. If the authors have no conflicts of interest, this should be stated. top ↑
Source ↗Publisher website ·- Data availability Data Sharing/Repositories
Wiley is committed to a more open research landscape, facilitating faster and more effective research discovery by enabling reproducibility and verification of data, methodology and reporting standards. We encourage authors of published articles to share their research data including, but not limited to: raw data, processed data, software, algorithms, protocols, methods, and materials. We expect t…
Source ↗Publisher website ·- Publication ethics Professional Conduct and Publication Ethics
The journal is committed to high standards for professional conduct and ethical behavior in all published material. The Publishing Ethics Guidelines detail the journal's position as a scientific publisher. Furthermore, the journal supports the International Guidelines for Ethical Conduct in Scientific Publishing (IUPAP) as they were adopted by the International Union of Pure and Applied Physics, t…
Source ↗Publisher website ·- Open access Open Access
A general exception to this rule is open access journals and articles, which have different agreements governing re-use of material. If you wish to reproduce materials from an open access title, you should check the journal homepage for more information on their re-use policies. CC-BY content can be used without asking permission, but the source must be attributed. Reproduced under terms of the CC…
Source ↗Publisher website ·- Peer review Peer Review Policy
All manuscripts are subject to assessment by the editors and/or peer review. The first evaluation of a manuscript rarely results in acceptance, but it is possible in exceptional cases. Manuscripts are rejected by the editors at this stage if they are insufficiently original, have serious scientific flaws, need extensive improvement in the language, or do not fall within the aims and scope of the j…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- ISSN
- 2366-3987
- Latest issue on the website
- Volume 9, Issue 9 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Advanced Therapeutics
What CAS zone is Advanced Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Advanced Therapeutics is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Advanced Therapeutics?
The latest impact factor listed by LetPub is 3.06; CiteScore 4.9, h-index 58.
How long does peer review take at Advanced Therapeutics?
Based on the dates recorded on 24 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 132 days (interquartile range 100–182 days); the journal's website gives an acceptance rate of 23% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Advanced Therapeutics?
According to the journal's author guidelines: Abstract: ≤ 200 words; Keywords: ≥ 3; Reference style: Numbered, in order of citation; Templates: LaTeX and Word; First submission: Free format: the journal's layout is not required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Advanced Therapeutics?
According to LetPub and DOAJ records, Advanced Therapeutics is indexed in SCIE and Scopus.
Is Advanced Therapeutics open access, and what is the APC?
Advanced Therapeutics is a hybrid journal. For open-access publication: APC about USD 4,430.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .